KR20220016865A9 - 항원 결합 분자, 약학 조성물, 및 방법 - Google Patents

항원 결합 분자, 약학 조성물, 및 방법

Info

Publication number
KR20220016865A9
KR20220016865A9 KR1020217040554A KR20217040554A KR20220016865A9 KR 20220016865 A9 KR20220016865 A9 KR 20220016865A9 KR 1020217040554 A KR1020217040554 A KR 1020217040554A KR 20217040554 A KR20217040554 A KR 20217040554A KR 20220016865 A9 KR20220016865 A9 KR 20220016865A9
Authority
KR
South Korea
Prior art keywords
methods
pharmaceutical compositions
antigen binding
binding molecules
molecules
Prior art date
Application number
KR1020217040554A
Other languages
English (en)
Other versions
KR20220016865A (ko
Inventor
히카루 고가
Original Assignee
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤 filed Critical 추가이 세이야쿠 가부시키가이샤
Publication of KR20220016865A publication Critical patent/KR20220016865A/ko
Publication of KR20220016865A9 publication Critical patent/KR20220016865A9/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217040554A 2019-05-15 2020-05-14 항원 결합 분자, 약학 조성물, 및 방법 KR20220016865A9 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2019092472 2019-05-15
JPJP-P-2019-092472 2019-05-15
JP2019155042 2019-08-27
JPJP-P-2019-155042 2019-08-27
PCT/JP2020/019177 WO2020230834A1 (en) 2019-05-15 2020-05-14 An antigen-binding molecule, a pharmaceutical composition, and a method

Publications (2)

Publication Number Publication Date
KR20220016865A KR20220016865A (ko) 2022-02-10
KR20220016865A9 true KR20220016865A9 (ko) 2022-02-21

Family

ID=73288884

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217040554A KR20220016865A9 (ko) 2019-05-15 2020-05-14 항원 결합 분자, 약학 조성물, 및 방법

Country Status (11)

Country Link
US (1) US20230002481A1 (ko)
EP (1) EP3969475A4 (ko)
JP (1) JP2022532282A (ko)
KR (1) KR20220016865A9 (ko)
CN (1) CN114096562A (ko)
AU (1) AU2020275348A1 (ko)
BR (1) BR112021021689A2 (ko)
CA (1) CA3137649A1 (ko)
IL (1) IL287920A (ko)
MX (1) MX2021013441A (ko)
WO (1) WO2020230834A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR120232A1 (es) * 2019-10-16 2022-02-09 Chugai Pharmaceutical Co Ltd Un anticuerpo, una composición farmacéutica y un método
CN117241828A (zh) 2021-03-31 2023-12-15 美国比奥维拉迪维股份有限公司 减少冷凝集素病患者的手术相关溶血

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
EP1725249B1 (en) 2003-11-06 2014-01-08 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
MY195714A (en) * 2008-04-11 2023-02-07 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable of Binding to Two or More Antigen Molecules Repeatedly
AU2012250924B2 (en) * 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
TW201326209A (zh) * 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CA3124553A1 (en) 2012-10-25 2014-05-01 Bioverativ Usa Inc. Anti-complement c1s antibodies and uses thereof
JP6543572B2 (ja) 2012-11-02 2019-07-10 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
WO2014186622A2 (en) * 2013-05-15 2014-11-20 Annexon, Inc. Methods of treatment for guillain-barre syndrome
MA41294A (fr) * 2014-12-19 2017-11-08 Chugai Pharmaceutical Co Ltd Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
EP3710589A4 (en) * 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHODS OF USE
WO2019198807A1 (en) * 2018-04-13 2019-10-17 Chugai Seiyaku Kabushiki Kaisha Anti-complement component antibodies and methods of use

Also Published As

Publication number Publication date
BR112021021689A2 (pt) 2022-03-22
CN114096562A (zh) 2022-02-25
MX2021013441A (es) 2021-12-10
WO2020230834A1 (en) 2020-11-19
US20230002481A1 (en) 2023-01-05
JP2022532282A (ja) 2022-07-14
IL287920A (en) 2022-01-01
KR20220016865A (ko) 2022-02-10
AU2020275348A1 (en) 2021-12-09
CA3137649A1 (en) 2020-11-19
EP3969475A4 (en) 2023-04-26
WO2020230834A8 (en) 2021-09-23
EP3969475A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
DK3476399T3 (da) Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf
IL262396A (en) New b7-h3 binding molecules, drug-antibody conjugates and their uses
EP3378871A4 (en) PD-L1 ANTIBODY, ANTIGEN FRAGMENT FOR BINDING THEREOF AND PHARMACEUTICAL USE THEREOF
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
CU20170169A7 (es) Anticuerpos de factor xi
BR112018010891A2 (pt) anticorpos e fragmentos de anticorpos para a conjugação específica do sítio
DK3337824T3 (da) Anti-bcma-antistoffer, bispecifikke antigen-bindende molekyler, som binder bcma og cd3, og anvendelse deraf
DK3356413T3 (da) Anti-tigit-antigenbindingsproteiner og fremgangsmåder til anvendelse deraf
EP3176181A4 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
DK3645570T3 (da) VISTA-antigenbindende molekyler
IL279015A (en) Anti-interleukin-17A antibody, its pharmaceutical preparation and its use
BR112016029579A2 (pt) anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
EP3256495A4 (en) Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
IL277848A (en) HER2-targeting antigen-binding molecules containing 4-1BBL
IL275798A (en) Methods for antibody drug conjugation, purification and formulation
DK3645571T3 (da) Her3-antigen-bindende molekyler
DK3362477T3 (da) Antigenbindingsproteiner, der aktiverer leptinreceptoren
IL280002A (en) Antibody molecules that bind CD137 and OX40
DK3380122T3 (da) Anti-5t4 antistoffer og antistoflægemiddel konjugater
EP3587452A4 (en) ANTI-TIM-3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF IT, AND MEDICAL USES OF IT
DK3269735T3 (da) Antistof mod sclerostin, antigenbindende fragment og medicinsk anvendelse deraf
KR20220016865A9 (ko) 항원 결합 분자, 약학 조성물, 및 방법
SG11202101435XA (en) ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF
MA48777A (fr) Nouvelles protéines de liaison à un antigène
EP3476864A4 (en) ANTIBODIES AGAINST ETAR, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Legal Events

Date Code Title Description
G170 Re-publication after modification of scope of protection [patent]
A201 Request for examination